CAMBRIDGE, Mass., December 03, 2025--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotection therapies against neurodegenerative diseases, today announced ...

Cognito Therapeutics is wrapping up the largest clinical trial ever conducted on a non-drug device for Alzheimer’s disease.

Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society. Cognito Therapeutics and West Virginia University’s ...

For decades, biotech companies have struggled to develop treatments for Alzheimer's disease, a disorder that causes loss of memory and other mental functions and affects roughly 6.5 million Americans.

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, and Aetion, a global real-world ...

Cognito Therapeutics is partnering with a nonprofit to “Change the D-Word,” aiming to eliminate the use of “dementia,” a catchall term that can carry stigma. The term “dementia” is an umbrella term ...

In a sea of failed Alzheimer’s treatments, a digital health startup is hoping to find answers in a noninvasive treatment using light and sound. Cognito was founded by MIT Professors Li-Huei Tsai and ...